Shannon Maude Research Program

Ongoing Research

Researchers are developing and evaluating chimeric antigen receptor (CAR)-modified T-cells to treat children with acute lymphoblastic leukemia (ALL). 

Early stage clinical trials in partnership with the Children’s Oncology Group (COG) are being developed to evaluate the efficacy and safety of a combination of ruxolitinib with standard chemotherapy to treat high-risk ALL with dysregulated Jak /STAT signaling mutations.